For global pharmaceutical professionals, the prospect of a Chinese company successfully navigating US biological drug approval for the first time signals a shift in competitive dynamics that extends well beyond a single drug class.
A subsidiary of Shenzhen-listed Yifan Pharmaceutical is positioning itself to challenge the global dominance of American biotech giant Amgen in the $5.5 billion market for post-chemotherapy treatments. Evive Biotech, the unit in question, is not merely seeking a foothold in a lucrative therapeutic area; it is aiming to become the first Chinese company ever to win US regulatory approval for a novel biological drug.
The therapeutic target is a class of drugs used to manage neutropenia, a common and dangerous side effect of chemotherapy that leaves patients vulnerable to infection. Amgen’s Neulasta and its biosimilars have long dominated this space, but Evive has developed a proprietary biologic candidate that it believes can compete on efficacy, safety, and cost. Chief executive Liu Jubo stated that the company is actively considering an initial public offering as early as 2021 to fund the final stages of clinical development and a potential commercial launch.
The strategic importance of this effort cannot be overstated. While Chinese contract development and manufacturing organizations have become integral to global biologics production, and while several Chinese companies have developed biosimilars for domestic markets, no Chinese firm has yet succeeded in bringing a wholly novel biologic across the US Food and Drug Administration’s rigorous approval threshold. A successful approval would validate that China’s biotech innovation ecosystem has matured to the point where it can originate and commercialize complex biological therapies for the world’s most demanding regulatory environment.
The global market for chemotherapy-support biologics is substantial and growing, driven by rising cancer incidence and expanding access to treatment in emerging economies. Breaking Amgen’s grip on this segment would not only unlock significant revenue for Evive and its parent company but could also open the door for a pipeline of other Chinese-originated biologics seeking entry into the US and European markets. For institutional investors and industry analysts, the company’s anticipated IPO provides a rare opportunity to gain direct exposure to this inflection point in Chinese biotech’s global ascent.
Why it matters:
The outcome of Evive Biotech’s regulatory campaign will serve as a bellwether for the broader Chinese biotech sector’s ability to move beyond contract manufacturing and biosimilar commoditisation into originator biologic drug development. A successful approval and subsequent market entry would reshape competitive dynamics in the oncology supportive care market and establish a precedent that could accelerate investment and regulatory engagement across the entire China-based biotech ecosystem.
ScientificChina — tracking what’s happening in Chinese science, technology, research, and industrial innovation in a way global professionals can actually use.
Follow ScientificChina for deeper insight into China’s evolving science, technology, and industrial landscape.
No products in the cart.